Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK
VANCOUVER, British Columbia, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group, Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, announces that it has completed its admission to the Access segment of the AQSE Growth Market (“AQSE”) and that trading commenced at 8:00 A.M. GMT on Tuesday, 10 October 2023 ("Admission") under the ticker "MYIG".
- Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.
- The Companies various families of Novel 2nd generation molecules are showing significant improvements over the first generation of psychedelic treatments. The Company has taken the approach that, in order to have a truly successful drug that is accessible by all, numerous modifications need to be made to the first generation MDMA or Psilocybin molecules, most notably shortening the half-life while keeping the experience integrity intact.
- The Company is currently working with its pre-clinical team at the University of Alberta to work these molecules through the Investigational New Drug enabling stage with the intent to put them into human clinical studies expected to commence in 2024.
- The Company has a comprehensive intellectual property strategy covering novel molecules, drug formulations, delivery mechanisms, and methods of production. The Company believes this covers all described drug development activities in our named pipeline and clinical trials. The Company has filed these applications both in the United States and through the Patent Cooperation Treaty (PCT) for protection in all jurisdictions in which the Company does business.
Josh Bartch, CEO of the Company stated, “We are incredibly excited to list our securities for trading in the UK on the AQSE Growth Market. We believe Mydecine is at a pivotal phase in its development and look forward to increased exposure to UK and European investors alike”.
The Company will have a dual listing with its common shares fully fungible through a CREST Depositary Interest ("CDI"). The CDIs will carry the same ISIN as the Common Shares listed in Canada on NEO. The issued share capital of Mydecine comprises 45,207,458 common shares.
The Company is classified as a Healthcare company on the Access Segment of the Aquis Stock Exchange.
This announcement, together with any documents incorporated by reference, shall be deemed to constitute an admission document for the purposes of the AQSE Growth Market Rules for Issuers – Access. It has not been approved or reviewed by the Aquis Stock Exchange or the Financial Conduct Authority.
The Directors are of the opinion, having made due and careful enquiry, that the working capital available to the Company is sufficient for a period of at least twelve months following admission.
The Directors of Mydecine take responsibility for this announcement.
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
Learn more athttps://www.mydecine.com.
For more information, please contact:
On behalf of the Board of Directors
Josh Bartch, Chief Executive Officer
AQSE Corporate Advisor
Novum Securities Limited Tel: +44 (0)207 399 9400
David Coffman/ George Duxberry
About Mydecine Innovations Group Inc.
Mydecine Innovations Group is a publicly traded, pre-revenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction, and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective, and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations. Mydecine developed several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. Mydecine is also developing MYCO-006—short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. Mydecine utilises cutting-edge artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them affordable and accessible to the general public upon Health Canada and FDA approval. The Mydecine team is enthusiastic about its mission and is dedicated to creating a positive difference in the lives of others.
Josh Bartch, Chief Executive Officer and Chairman
Josh Bartch is Director, Chief Executive Officer, and Chairman of Mydecine Innovations Group (MIG). His entrepreneurial career commenced in 2009 when he cofounded AudioTranscriptionist.com and founded the Denver-based dispensary, Doctors Orders. Following these ventures, Josh founded a boutique investment firm that operated throughout the U.S. and Canadian markets. In 2014, he co-founded Cannabase.io, the U.S.’s most significant legal and sophisticated cannabis wholesale platform. He made successful exits from AudioTranscriptionist.com, Doctor’s Orders, and Cannabase.io.
Robert Roscow, Chief Science Officer
Robert is Chief Science Officer of Mydecine bringing his diverse background in biology, biotechnology, policy and intellectual property to innovation in the mycology space. Robert’s substantial expertise includes genetic engineering, molecular biology, bioinformatics, plant breeding and tissue culture, photomicroscopy, unicellular microinjection, fish husbandry and breeding colony maintenance and
Following academic work studying the genetic dynamics of cellular patterning, Robert applied his advanced knowledge to cannabis plant enhancement. He joined ebbu in 2015, where he created IP related to the commercial optimisation of Cannabis sativa, industrial hemp and hops, resulting in three pending US patents.
In 2019 Rob oversaw the design, build and staffing of a plant analytical chemistry laboratory in Ontario, Canada, for Canopy Growth Corporation where he was Lead Director of Genetic Research. He also participated in the Colorado Hemp Advancement & Management Plan Initiative Cannabis Industry as an industry stakeholder in 2019.
Neil Stevenson-Moore, Non-Executive Director
Neil is an experienced executive and thought leader in the technology community. He has a track record of driving growth, success and innovation and has worked in both corporate and entrepreneurial environments. For the past 15 years he has founded, led, and advised companies in consumer focused and medical tech industries including House of Kibaa, SportNinja, Farfetch and StylePixi He has successfully raised tens of millions of dollars from private investors, community partners, and government organisations. Neil holds a Bachelor of International Politics from Princeton University and has additional coaching certifications. He is fluent in French and proficient in Spanish.
This news release contains forward-looking information about Canadian securities laws regarding the Company and its business. It relates to future events or performance and reflects management’s expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect,” “intends,” “anticipated,” “believes,” or variations (including negative variations) of such words and phrases or by stating that specific actions, events, or results “may,” "could," "would,” or “will” be taken, occur, or be achieved.
Such forward-looking statements reflect management’s beliefs and are based on assumptions and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected, including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to protect and enforce its intellectual property adequately, the Company's ability to bring its products to commercial production, the continued growth of the global adaptive pathway medicine, natural health products, and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale, and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, other factors may cause effects not to be as anticipated, estimated, or intended. There can be no assurance that such information will be accurate, as actual results and future events could differ materially from those anticipated. These forward-looking statements are made as of the date hereof. The Company is not obligated to update or revise them to reflect new events or circumstances as required under applicable securities legislation.
This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
MYDECINE INNOVATIONS GROUP, INC.
Suite 810–789 West Pender Street, Vancouver, British Columbia, V6C 1H2 T: 604-687-2038
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Teledyne’s Contact Image Sensors for high-speed, high-resolution line scan are now in production30.11.2023 14:00:00 CET | Press release
WATERLOO, Ontario, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Teledyne DALSA is pleased to announce that its AxCIS™ family of high-speed and high-resolution fully integrated line scan imaging modules are in production. These easy-to-use Contact Image Sensors (CIS) combine sensors, lenses, and lights all-in-one, offering a lower cost inspection system for many demanding machine vision applications. Powered by Teledyne’s multiline CMOS image sensors, AxCIS delivers superior image quality, up to 120 kHz line rates for mono, or 60 kHz x 2 for HDR imaging, at a pixel size of 28 µm or 900 dpi resolution, so that defects can be detected with unprecedented precision. Its unique sensor design covers the entire field of view without missing pixels, providing a 100% seamless image without any interpolation. HDR imaging is achieved using dual rows with independent exposure control, which enables better detectability for highly reflective materials with improved dynamic range. In addition to defect detectio
XPENG G9 awarded Norway's People's Favorite Car of the Year Award30.11.2023 13:59:01 CET | Press release
OSLO, Norway, Nov. 30, 2023 (GLOBE NEWSWIRE) -- XPENG Motors ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading Chinese smart EV company, becomes the first Chinese car brand to win "People's Favorite 2024", also known as 'folkets favoritt', with the XPENG G9 in Norway's renowned “Car of The Year” awards. "People's Favorite" is part of the prestigious award "Car of the Year 2024" which is carried out for the nineteenth year in a row by Dagbladet in collaboration with media publications Dinside and Elbil24. Readers of Dagbladet, Dinside and Elbil24 in Norway voted for their favorite car for a month, with the XPENG G9 winning with 15.22 percent of the vote. Managing Director of XPeng Motors Norway, Claes Persson, expressed gratitude for this award: "We consider this to be an incredibly distinguished award, especially because the people chose us as the winner. We look forward to developing our current and upcoming electric car models further." Editor in Elbil24, Fred Magne Sk
Delårsrapport for perioden 1. juli – 30. september 202330.11.2023 13:45:00 CET | pressemeddelelse
Nasdaq OMX Copenhagen A/S Charlottenlund, den 30. november 2023 Meddelelse nr. 246 Delårsrapport for perioden 1. juli – 30. september 2023 Bestyrelsen har dags dato behandlet og vedtaget vedhæftede delårsrapport for 3. kvartal 2023. Resultat før værdiregulering og skat for perioden 1. juli til 30. september 2023 udgjorde et overskud på T.EUR 40,0. Resultatet anses som forventet.Negativ værdiregulering på de tyske ejendomme på EUR 3,0 mio.Der er i perioden 1. juli til 30. september 2023 afdraget ekstraordinært EUR 1,0 mio. på lånet hos Ringkjøbing Landbobank, så der samlet for perioden 1. januar til 30. september 2023 er afdraget ekstraordinært i alt EUR 2,0 mio. på lånet hos Ringkjøbing Landbobank.Fortsat betryggende soliditet på 56,4% og likvide reserver på TEUR 3.467,0.Set i lyset af et stadig højt renteniveau forventes et positivt resultat før værdiregulering og skat at ligge i den nedre ende af det udmeldte interval på TEUR 200,0 – 600,0 i 2023.Fokus på fastholdelse af lejere og le
EBVAT for 3. kvartal 2023 – 4,9 mio. kr.30.11.2023 13:44:15 CET | pressemeddelelse
Den 30. november 2023 EBVAT i perioden 1. januar til 30. september 14,9 mio. kr. Samlet resultat er -219,9 mio. kr. i 3. kvartal 2023, Værdiregulering i 3. kvartal 2023 udgør -224,8 mio. kr. Perioden 1. januar til 30. september 2023 For perioden 1. januar til 30. september er det samlede resultat før skat -246,6 mio. kr. Resultatet før kurs- og værdireguleringer (EBVAT) udgør 14,9 mio. kr. Perioden 1. juli til 30. september 2023 EgnsINVEST Ejendomme Tyskland A/S har i 3. kvartal 2023 realiseret et resultat før skat på i alt -219,9 mio. kr., hvoraf -224,8 mio. kr. kan henføres til dagsværdiregulering af investeringsejendomme. Resultatet før kurs- og værdireguleringer (EBVAT) er på 4,9 mio. kr. i perioden. Med baggrund i ejendomsværdireguleringen er selskabets indre værdi faldet med 24,87% til 234,01 i perioden 1. juli til 30. september og børskursen er faldet med 19,47% fra 226 til 182. Selskabets tomgang er 1,06% for boliger og 6,82% for erhverv pr. 30. september, i alt 1,66% (14 lejem
Update: Virtune AB (Publ) is launching Virtune Chainlink ETP on Nasdaq Stockholm30.11.2023 13:35:16 CET | Press release
Stockholm, November 30th, 2023 - Virtune, a Swedish regulated digital asset manager in Sweden is launching a new innovative crypto ETP on Nasdaq Stockholm, the largest stock exchange in the Nordic region. Today, Virtune is announcing the introduction of Virtune Chainlink ETP, providing exposure to Chainlink through a proven and well established financial instrument with a 100% physically backed structure. The ETP which is 100% physically backed and fully collateralized is denominated in SEK for the Swedish audience and is available on Avanza and Nordnet. Chainlink is currently among the top 15 largest cryptocurrencies with a market capitalization of about USD 8,2 billion and has experienced a 165% growth during 2023 year to date. Chainlink acts like a bridge for smart contracts on different blockchains, making them all work together. It does this using a decentralized oracle network, which helps blockchains talk to external things like data feeds, events, and payment methods in a secur